OCV
OCV is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at OCV.
OCV is a company.
Key people at OCV.
Key people at OCV.
OCV Partners is a Los Angeles-based venture capital firm founded in 2016 that invests in early- to mid-stage companies with differentiated technologies in compelling markets, focusing on Technology (SaaS, FinTech, PropTech) and Healthcare (Healthcare SaaS, Digital Health, MedTech, BioTech).[1][2][5] The firm's mission centers on leveraging decades of company-building experience from former founders to create asymmetric advantages for portfolio companies, emphasizing hands-on support, operational efficiency, and backing transformative teams with recurring revenue models.[2][3] With approximately $260.8M raised across funds, OCV has made 20 investments, achieved 4 portfolio exits, and continues active deal flow, including recent rounds like ByHeart's Series D in March 2025 and Rad AI's Series C in January 2025, significantly impacting the startup ecosystem through strategic introductions and growth acceleration.[1][3]
OCV Partners was founded in 2016 by partners including Richard Ressler (Co-Founder and Chairman), Hemi Zucker (Managing Partner), Andy Liu (Partner), and Chris Bostick (Partner), drawing on their backgrounds as former founders, scientists, and healthcare entrepreneurs who have scaled businesses to IPOs, grown over 165 software companies, and built expertise in tech and health sectors.[2][5] The firm emerged from a desire to apply this operator experience to identify and nurture high-potential startups, evolving from a flexible capital provider—willing to lead rounds or join syndicates—to a hands-on investor focused on creating outsized advantages in subscription software, FinTech, PropTech, and disruptive healthcare platforms.[2][3] Early traction included investments like OSSIO's $22M round in 2019, where OCV led and placed a principal on the board, signaling their operational involvement from inception.[3]
OCV rides the wave of AI-driven transformation in healthcare and scalable SaaS/FinTech models, capitalizing on post-pandemic demand for digital health platforms that enable precision medicine, workflow optimization, and barrier-free care amid rising healthcare costs and tech adoption.[2][3] Timing aligns with maturing PropTech for real estate digitization and BioTech accelerations, where market forces like regulatory clearances (e.g., OSSIO's 510(k)) and investor appetite for growth-stage deals favor their mid/late-stage focus.[3] By backing 20+ companies and influencing exits, OCV shapes the ecosystem through operator networks, fostering innovation at tech-health intersections and supporting equitable, tech-enabled human health advancements.[2]
OCV's trajectory points to expanded dealmaking in AI-enhanced Healthcare SaaS and FinTech, building on 2025 momentum like ByHeart and Rad AI to pursue more Series C/D opportunities amid favorable VC recovery and health tech tailwinds.[3] Trends like precision therapeutics and PropTech scalability will amplify their asymmetric advantages, potentially growing AUM beyond $260M via new funds while evolving influence through deeper operating roles in portfolio scaling. This positions OCV as a pivotal backer for extraordinary founders navigating tech-health convergence, echoing their founding promise of transforming compelling markets.[2]
